Latest News of ZYME
Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec
By Yahoo! Finance |
1 day ago
Halozyme Therapeutics withdraws its bid to acquire Evotec SE for 2 billion euros due to lack of engagement. Evotec remains focused on its standalone strategy for growth and profitability, despite inte...
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
By MarketWatch |
6 days ago
Halozyme proposed a non-binding takeover of Evotech SE at 11 euros a share, valued at €2 billion. The combined company aims for $2 billion in revenue by 2025, creating a unique pharma services compa...
ArcticZymes Technologies ASA (FRA:B4V) Q3 2024 Earnings Call Highlights: Navigating Challenges ...
By Yahoo! Finance |
2 weeks ago
ArcticZymes faces challenges in a tough macroeconomic climate, impacting smaller gene and cell therapy biotechs. The company plans strategic investments led by new VP of Sales to accelerate market pen...
-
Zymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
By Yahoo! Finance | 3 weeks agoThe company plans to optimize doses by exploring alternatives and carrying multiple doses into the expansion phase. They aim to develop combination therapies based on wider therapeutic index and aim t...
-
ArcticZymes Technologies ASA (FRA:B4V) Q2 2024 Earnings Call Highlights: Record Orders and ...
By Yahoo! Finance | 1 month agoThe CEO discusses evaluation orders, CDMO supply agreement, nucleases usage, strategic priorities, and regulatory compliance in the earnings call. ArcticZymes aims to enhance sales, partnerships, and ...
-
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 2 months agoRoche has gained FDA approval for OCREVUS ZUNOVO™, a treatment for multiple sclerosis using Halozyme's ENHANZE® drug delivery technology. The medication is administered as a subcutaneous injection ...
-
FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech
By Yahoo! Finance | 2 months agoRoche's Ocrevus Zunovo, utilizing Halozyme's Enhanze technology, received FDA approval for subcutaneous injection to treat multiple sclerosis. The new method offers flexibility and efficiency, with co...
-
Inozyme Pharma, Inc. (INZY) Stock Price, News, Quote & History
By Yahoo! Finance | 3 months agoInozyme Pharma specializes in developing treatments for rare diseases affecting vasculature, soft tissue, and skeleton. Their lead product, INZ-701, targets ENPP1 and ABCC6 deficiencies and end-stage ...
-
Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)
By Yahoo! Finance | 3 months agoMatthew Posard, Director at Halozyme Therapeutics Inc, sold 29,881 shares on August 14, 2024, bringing his total ownership to 69,874 shares. The company focuses on oncology therapies targeting the tum...
-
Zymeworks Inc. (NASDAQ:ZYME) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
By Yahoo! Finance | 3 months agoZymeworks Inc. recently reported disappointing quarterly results, missing revenue predictions. Analysts now expect a significant revenue increase in 2024, but also predict larger losses. Despite this,...
-
Lululemon backs plastic-eating enzyme innovation from Samsara Eco
By Yahoo! Finance | 4 months agoSamsara Eco uses AI to develop plastic-eating enzymes that can break down plastics for infinite recycling. With $65m funding, it plans to build recycling facilities in Southeast Asia with partners lik...
-
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
By Yahoo! Finance | 4 months agoA list of top biotech penny stocks includes Inozyme Pharma, Inc. (NASDAQ:INZY) showing promise in rare disease therapeutics. Analysts rate it a Strong Buy with potential for significant growth....
-
Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
By Yahoo! Finance | 4 months agoInvesting in quality companies like Halozyme Therapeutics can lead to significant gains, such as a 193% increase in share price over five years. However, careful analysis of fundamentals is crucial fo...
-
Zymeworks (NASDAQ:ZYME) investors are sitting on a loss of 75% if they invested three years ago
By Yahoo! Finance | 5 months agoZymeworks Inc. (NASDAQ: ZYME) has seen a significant 75% drop in share price over the last three years, with a 16% decrease in the last 90 days....
-
Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO)
By Yahoo! Finance | 5 months agoHalozyme Therapeutics Inc is a biopharmaceutical company focusing on oncology therapies targeting the tumor microenvironment. Insider transactions show 17 sells and no buys in the past year. Shares va...